<DOC>
	<DOC>NCT00768131</DOC>
	<brief_summary>The purpose of this study is to determine if EGFR status (positive or negative) by FISH can predict response to cetuximab therapy in NSCLC patients treated with carboplatin and paclitaxel</brief_summary>
	<brief_title>A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Subjects who present with Stage IV, Stage IIIB NSCLC or recurrent disease following radiation therapy or surgical resection No prior chemotherapy or antiEGFR targeted therapy Sufficient tumor material for FISH testing Measurable disease (RECIST) ECOG performance status 0 or 1 Symptomatic or uncontrolled CNS metastases Inadequate hematologic function defined as ANC &lt; 1,500/mm3, platelet count &lt; 100,000/mm3, or a hemoglobin level &lt; 9 g/dl Inadequate hepatic function defined as total bilirubin &gt; 1.25 x ULN, AST level &gt; 1.5 x ULN, or alkaline phosphatase &gt; 5.0 x ULN Inadequate renal function defined by a serum creatinine level &gt; 1.5 x ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>